Clear Cell Renal Cell Carcinoma Clinical Trials in Duarte, California

5 studies are recruiting for clear cell renal cell carcinoma in Duarte, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

   This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

   Locations

   162 in total

   Run by

   Pfizer

   See if you can join NCT07227415 on ClinicalTrials.gov

2. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

   This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   425 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06661720 on ClinicalTrials.gov

3. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

   The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Xencor Investigative Site, Duarte, California

   Locations

   26 in total

   Run by

   Xencor, Inc.

   See if you can join NCT05433142 on ClinicalTrials.gov

4. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

   The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEO-811 Los Angeles Site, Duarte, California

   Locations

   12 in total

   Run by

   Neomorph, Inc

   See if you can join NCT07300241 on ClinicalTrials.gov

5. Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

   This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibitor. Immunotherapy wi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   2 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07037004 on ClinicalTrials.gov